QuikChange Site-Directed Mutagenesis Kit, 10 Rxn

Site Directed Mutagenesis (SDM) Human - Point mutation IMR-32 OPTN

Experiment
Site Directed Mutagenesis (SDM) Human - Point mutation IMR-32 OPTN
Product
QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies
Manufacturer
Agilent Technologies

Protocol tips

Upstream tips
- XL10-Gold cells are resistant to tetracycline and chloramphenicol. If the mutagenized plasmid contains only the tetR or camR resistance marker, an alternative strain of competent cells must be used.
Protocol tips
- Use only the Dpn I enzyme provided; do not substitute with an enzyme from another source.

Publication protocol

Expression Vectors
Plasmid vectors for expressing human OPTN and its mutants (M98K and M98K-D474N) with HA and GFP-tags have been described [, ]. HA-S177A-OPTN and HA-M98K-S177A-OPTN mutants were made by site-directed mutagenesis from HA-OPTN and HA-M98K-OPTN respectively, following the protocol described in QuikChange Site-Directed Mutagenesis Kit (Stratagene/Agilent). S177A-OPTN and M98K-S177A-OPTN were cloned in pEGFP-C3 (Clontech, 6082–1) to produce GFP-tagged OPTN mutants. cDNA of mouse was amplified by RT-PCR using RNA from RGC-5 cells and cloned in pcDNA3.1 and EGFP vectors. GFP-K38A-Tbk1 and HA-K38A-Tbk1 were made by site-directed mutagenesis from GFP-Tbk1 and HA-Tbk1 respectively. The plasmids, pDest-GFP-LC3B and mCherry-GFP-LC3B were kindly provided by Dr. Terje Johansen (University of Tromsø, Tromsø, Norway) []. Adenoviral vectors expressing wild-type OPTN and its M98K, M98K-D474N and E50K mutants have been described earlier [, ].

Full paper   Login or join for free to view the full paper.

Reviews

QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Site Directed Mutagenesis (SDM) Human - Point mutation IMR-32 OPTN using QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies.

Paper title
A Glaucoma-Associated Variant of Optineurin, M98K, Activates Tbk1 to Enhance Autophagosome Formation and Retinal Cell Death Dependent on Ser177 Phosphorylation of Optineurin
Full paper
Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Agilent Technologies for QuikChange Site-Directed Mutagenesis Kit, 10 Rxn below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing Site Directed Mutagenesis (SDM) Human - Point mutation IMR-32 OPTN using QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Become shareholder Discussions About us Contact Privacy Terms